Compare BGY & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BGY | AUTL |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.1M | 596.2M |
| IPO Year | N/A | 2025 |
| Metric | BGY | AUTL |
|---|---|---|
| Price | $5.39 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.73 |
| AVG Volume (30 Days) | 314.4K | ★ 1.6M |
| Earning Date | 01-01-0001 | 11-10-2026 |
| Dividend Yield | ★ 7.41% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,120,000.00 |
| Revenue This Year | N/A | $98.68 |
| Revenue Next Year | N/A | $28.47 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 496.00 |
| 52 Week Low | $5.19 | $1.18 |
| 52 Week High | $6.23 | $2.58 |
| Indicator | BGY | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 36.35 | 35.84 |
| Support Level | $5.19 | $1.37 |
| Resistance Level | $5.85 | $1.56 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 19.57 | 15.62 |
Blackrock Enhanced International Dividend Trust is a diversified closed-end management investment company. Its primary investment objective is to provide current income and current gains, with a secondary objective of long-term capital appreciation. The Trust invests the majority of its net assets in dividend-paying equity securities issued by non-U.S. companies of any market capitalization, with a key focus on securities of large capitalization companies. It invests directly in such securities or synthetically through the use of derivatives.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.